Teams at the Trust were awarded a Health Service Journal Partnership Award for their work with digital health start-up NuvoAir to improve the lives of people with cystic fibrosis (CF).
Working in partnership with Royal Brompton, NuvoAir designed a patient platform with a clinician-facing portal to be used to self-monitor lung function, archive data and share this with clinical teams during virtual consultations.
Key to this new service is the NuvoAir spirometer, a device that can be used at home to measure lung function (a measure of lung health) and, via Bluetooth, allows the results to be seen on patients’ mobile phones or tablets. The results can then be shared with the specialist CF clinical team at Royal Brompton during virtual consultations, which can replace some outpatient appointments.
The platform and virtual service were developed following patient surveys of adults with CF attending the hospital. The research highlighted the impact of attending regular appointments on adults with CF, their family, careers and/or dependants. National guidelines recommend that all children and adults with CF attend their specialist CF centre at least four-six times a year.
Royal Brompton Hospital’s consultant nurse in cystic fibrosis, Dr Susan Madge, said:“We’re thrilled to receive this award which recognises the important work we’ve been doing to reduce both financial and time burdens for adults with CF.
“Patients were the driving force for this partnership and were at the centre of the design and build process. We wanted to put adults with CF back in the driving seat, to let them have ownership of their data and deliver virtual consultations to lead the way in changing the care delivered to adults with CF.
“Giving patients the ability to measure their own lung health has reduced the need for them to come to the hospital so often. It means they have a better idea of how stable they are and if new treatments are working. We can then have conversations about their data over the phone or the internet instead of bringing them to clinic, making better use of our time and theirs.”
Experts welcome access to cystic fibrosis drugs >